Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 5Neoplasms 4Astrocytoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Glioblastoma 3Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Medulloblastoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hereditary Breast and Ovarian Cancer Syndrome 2Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Brain Neoplasms 2

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solid Neoplasm × veliparib × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡